Pharma Tech

A Vision for the Global Generic and Biosimilar Medicines Industry

May 22, 2021

A Vision for the Global Generic and Biosimilar Medicines Industry
One of the key roles of the generic and biosimilar medicines industry is specifically to promote
the widest possible access to affordable medicines with high quality, safety, and efficacy for
patients globally by introducing competition into the markets. Despite the many hurdles, the
generic medicines companies have clearly lived up to the challenges posed by the pandemic
as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the
outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive
Care Units to ventilate critically ill COVID patients. It is also providing most of the quality
medicines dispensed around the world, especially for increasingly prevalent chronic diseases
and is therefore a strong contributor to health outcomes globally.

Spotlight

Aptalis Pharmaceutical Technologies (now Adare Pharmaceuticals)

We would like to invite you to follow our new Adare Pharmaceuticals page at.

OTHER WHITEPAPERS
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
news image

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Read More
news image

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Read More
news image

How to optimize clinical supply chain management with Slope

whitePaper | December 15, 2022

Successful execution of clinical trials requires the orchestration of multiple moving parts, with everything from protocol design and patient visit schedules, to lab kits and biological samples needing to seamlessly line up to ensure on-time, on-budget delivery of high-quality data.

Read More